What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach? - Chemoradiation followed by surgery Bruce Minsky.

Slides:

Advertisements

Similar presentations

Advances and Emerging Therapy for Lung Cancer

Advertisements

Highligths in management of gastrointestinal cancer April 11, 2008 CONTROVERSIES IN THE CONTROVERSIES IN THE ADJUVANT THERAPY ADJUVANT THERAPY OF GASTRIC.

Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.

Carcinoma of the Cardia: Is there progress in the management of non-Barrett’s cancer Spanish Association of Surgeons Madrid 11 November 2002 The University.

Rectal Cancer: Advanced Technologies Chris Willett, M.D. Department of Radiation Oncology Duke University Medical Center Durham, NC.

Statements on Head and Neck Cancer 2006 Primary Radiochemotherapy Arlene A. Forastiere, M.D. Johns Hopkins University School of Medicine Department of.

DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.

Management of Pancreato- biliary Malignancy: Medical Oncology Perspective Robert A. Wolff, MD Professor of Medicine Department of GI Medical Oncology.

Early Stage NSCLC: The Role of Chemotherapy Eric Vallieres, MD.

A BALANCED APPROACH TO THE TREATMENT OF ESOPHAGEAL CANCER.

Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.

ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.

Upper Gastrointestinal Overview : Practical Implications of the Newest Data Esophageal and Gastric Cancers Johanna Bendell, MD Sarah Cannon Research.

21th WCC, Shenzhen, China, Aug 19, 2010 Guo-Liang Jiang, MD, FACR Min Fan, MD, Jiayan Chen, MD Fudan University Shanghai Cancer Center Combination of radiation.

Anal Cancer Rob Glynne-Jones Mount Vernon Cancer Centre on behalf of NCRI anal cancer subgroup.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Esophageal Cancer, New updates in Chemoradiation Dr Hamid Reza Dehghan Manshadi Radiation Oncologist Iran University of Medical sciences.

Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.

Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.

Prof Ramesh S Bilimagga President AROI Group Medical Director - HCG.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

GIC Protocol Meeting Ca Stomach Presentor-Dr Richa Madhawi Moderator- Dr S. Pathy.

AATS/STS General Thoracic Surgery Symposium

1 Non–Small-Cell Lung Cancer Diagnosis and Staging EvaluationPurpose Physical examinationIdentify signs Chest x-rayDetermine position, size, number of.

Intergroup trial CALGB 80101

Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,

Taiwan 2000 Should all patients be treated with adjuvant and/or neoadjuvant treatment? Arnaud Roth MD Oncosurgery Geneva Switzerland Gastric Barcelona.

Post-Resection CA 19-9 Predicts Overall Survival in Patients Treated with Adjuvant Chemoradiation; RTOG 9704 A. Berger, K. Winter, J. Hoffman, W. Regine,

What to do in stage III non small-cell lung cancer? Miklos Pless 28. November 2013.

What is the Preferable Treatment Option for T1/T2 Low Rectal Cancer? Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology.

Gastric Cancer Gidon Almogy MD Department of General Surgery Hadassah University Hospital.

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.

MANAGEMENT OF ESOPHAGEAL CANCER Elshami Elamin, MD Medical Oncologist Central Care Cancer Center Newton, KS - USA.

Rectal Cancer: French Prodige Study: Best of ASCO, Beirut, July 2009 Prof Eric Van Cutsem, MD, PhD Digestive Oncology Leuven, Belgium.

Taiwan 2000 Comparative evaluation in tolerance of neoadjuvant versus adjuvant docetaxel based chemotherapy in resectable gastric cancer in a randomized.

Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.

CJ Allegra, G Yothers, MJ O’Connell, MS Roh, RW Beart, NJ Petrelli, S Lopa, S Sharif, and N Wolmark Neoadjuvant Therapy For Rectal Cancer: Mature Results.

Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl,

Michael Stahl on behalf of the German Oesophageal Cancer Study Group PreOperative Chemotherapy or Radiochemotherapy in Esophago- gastric Adenocarcinoma.

Approaching early stage disease

Poster # 18, abstract # 4530 Long term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous.

Adjuvant Therapy of Colon Cancer: Where are we now ? Leonard Saltz, MD Memorial Sloan Kettering Cancer Center New York, NY.

Preliminary Results of the MRC CR07 / NCIC CO16 Randomized Trial Short course pre-op vs selective post-op chemo-RT for rectal cancer Local Recurrence after.

Dr Mark Saunders Christie Hospital and Paterson Institute of Cancer Research “ Rectal cancer radiotherapy – why do we give it and how do we do it?”

Patterns of Care in Medical Oncology Treatment of Metastatic Colon Cancer.

The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.

Upper Gastrointestinal Cancers Overview : Review of the Latest Data and Practice Implications Esophageal and Gastric Cancers Johanna Bendell,

Neoadjuvant FOLFOX with Bevacizumab but without Pelvic Radiation for Locally Advanced Rectal Cancer Schrag D et al. Proc ASCO 2010;Abstract 3511.

Seasoning with... CPPD, 5FU? Uhm... Chopped Chopped first or at the end? BBQed, Steamed or microwaved Then... cooked or..... Marinating? With Taxanes,

Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.

Multidisciplinary treatment of rectal cancer. Medical oncology Carlo Aschele E.O. Ospedali Galliera – Genova - Italy Carlo Aschele E.O. Ospedali Galliera.

Rectal Cancer MOTP Half Day September 9, 2008

Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,

Emily Tanzler, MD Waseet Vance, MD

Treatment options for HPV+ disease

Perez EA et al. SABCS 2009;Abstract 80.

นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี

Advances in esophageal cancer: Current and future strategies

What is the most appropriate therapy for a 50 year old patient with T3N+ rectal cancer and isolated resectable liver metastases? Systemic chemotherapy->chemoradiation->surgery.

What is the optimal pre-op therapy for esophagus and GE junction cancers?

Oesophageal and Gastric cancer: neo-adjuvant therapy

Adjuvant Radiation is Required for Gastric Cancer

Alan P. Venook, MD University of California, SF

Adjuvant Therapy in Gastric Cancer: Radiation Therapy Adds Nothing!

Neoadjuvant Adjuvant Curative Palliative

Do all patients with T2-3 mid-high rectal adenocarcinomas require RT as part of their neoadjuvant therapy? - Yes -   Bruce Minsky.

Michael Stahl on behalf of the German Oesophageal Cancer Study Group

RTOG 9704: A Phase III Study of Adjuvant Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Resected Pancreatic Adenocarcinoma A U.S. GI INTERGROUP.

Presentation transcript:

What is the optimal sequence of therapies for stage II-III adenocarcinoma of the proximal stomach? - Chemoradiation followed by surgery Bruce Minsky

INT 0116 Adjuvant Gastric Trial T3 and/or N1-2 (85%) 20% GEJ 54% D 0 5-FU/LV x Gy Surgery alone CMTSURGERY 3-Year Survival (%)4030** Local Failure (%)1929

INT 0116 – 10.3 Yr Median F/U Smalley et al JCO 2012

Postop RT Fields

Acute Toxicity – INT 0116 %Toxicity 33 Gr 3-4 Diarrhea 54 Gr 3-4 Neutropenia 1 Death 65% Completed all therapy 17% Stopped for toxicity

Postop S1 (ACTS-GC) Sasaco et al JCO 2011 · 1059 pts, Stage II/III · D2 resectionS1 Wks 1-4, q 6 weeks x 1 yr · Gr 3+ toxicity < 5% % 5-Yr % LR Survival FailureHR Surgery only Postop S

Upper GI Adenocarcinomas Overlap of GE Junction and Gastric (Siewert II and III) 20% GE junction in INT 0116 Preop CMT for GE junction

Adjuvant Preop RT Zhang IJROBP pts, clinically resectable disease % 5-Yr % Failure %R0 SurvivalLocalLN Surgery Gy80* 30*3331

Phase III Preop CT +/- CMT for GE Junction Adeno Stahl et al JCO 2009 · 119/126 eligible pts T3-4Nx GE junction (Siewert I-III) FU/LV/CDDP X 2.5 FU/LV/CDDP VP-16/CDDP X Gy (2 Gy/d) Surgery

Phase III Preop CT +/- CMT for GE Junction Adeno Induction ChemotherapyChemoRTP # Entered4945 % R0 Resection % Mortality410 - % pCR Yr Survival % 3-Yr Local Fail

Preop CMT for Gastric 43 pts EUS T2-3 and/or N1-2, lap negative 5FU/LV/CDDP x 2 then 45 Gy/5FU/Paclitaxel 36 had surgery (7 POD), 50% D2 26% pCR 21% Gr 4 toxicity 23 M median survival RTOG 9904 JCO 2006

CROSS Study Group Van Hagen NEJM 2012 ∙ 368 pts ∙ 75% Adeno ∙ T1N1 or ∙ T2-3N0-1 Surgery Preop paclitaxel/carboplat Concurrent 41.4 Gy (1.8 Gy/d) ∙ pCR: 29% (adeno: 23% vs. 49% SCC), 4% mortality R0 % 5-Yr S Preop`9259 Surg6948 p<0.003 p=0.001

CROSS I + II Trials  422 Pts, 374 underwent surgery  75% adeno  F/U: 45 M median, 24 M min #%LR%PS%DF Preop p<0.001 p<0.001 p=0.025 Surg14429  5% LR (1% isolated) in the RT field Oppedijk et al, JCO 2014

SCOPE1: CMT+ Cetuximab ∙ 258 Pts, Stage I-III ∙ (97% stage II,III) ∙ 25% Adeno 50Gy/CDDP/Cape + Cetuximab ∙ Stopped early – met futility % 2-YrMedian% Gr 3+ CetuximabSurvivalSurvivalNon-heme Toxicity Yes4122 m79 No5625 m63

RTOG 1010

Conclusions Postop CMT increases survival Overlap between GE junction and gastric Preop CMT improves survival (CROSS) Preop RT fields are smaller (no postop bed)